Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Acceleron Pharma Inc (NASDAQ:XLRN) shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes.
The candidate also posted positive results in a late-stage trial that evaluated it for transfusion-dependent beta thalassemia.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Analyst
The rally sent Morgan Stanley analyst Matthew Harrison to the sidelines. He downgraded Acceleron from Overweight to Equal-weight and maintained a $50 price target.
The Thesis
Acceleron's luspatercept data is strong, positioning the company for a filing in the first half of 2019, but there is possibility of limited near-term upside, Harrison said in a Friday morning note. (See the analyst's track record here.)
Harrison's view that the novel TGF-beta platform is a better way to treat anemia has largely materialized following the positive data reported for the two indications, he said. The analyst projects limited upside until more details are presented on the magnitude of the efficacy response and safety, which is likely to come at the December American Society of Hematology meeting.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
"Other catalysts include initial data on ACE-083,including the final dose-escalation results in [the second half of 2018] as well as initial ACE2494 data in [the first half of 2019."
With both Phase 3 readouts now reflected in Acceleron's valuation, Harrison said the stock has a more balanced risk-reward profile.
Key upside drivers include luspatercept data, which could notably increase sales estimates, or data from the early stage pipeline, which is not reflected in Acceleron's valuation, the analyst said.
The Price Action
Acceleron shares have added about 11 percent year-to-date.
Related Links:
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.